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Summary
Background.— An ageing population and the extension of indications will in all probability result
in an increasing number of cardiac device implantations.
Methods.— Patients implanted in 2008 and 2009 were identiﬁed by means of the French National
Hospital Discharge database to establish the implantation rate and the National Health Insurance
(NHI) Information System database for patient proﬁles (76% of the population).
Results.— Of the 64,306 pacemaker implantations (1003.7 per million inhabitants [pmi]) in
2009, 21.4% were single chamber, 75.4% double chamber and 3.2% triple chamber (CRT-
P). Of the 9028 cardioverter-deﬁbrillator implantations (140.8 pmi) in 2009, 30.1% were
single chamber, 27.5% double chamber and 42.5% triple chamber (CRT-D), accounting for
65% of cardiac resynchronization therapy (CRT) implants. Among NHI beneﬁciaries, 58.6% of
cardioverter-deﬁbrillators were implanted for primary prevention. Between 2008 and 2009,
CRT-P implantations increased by 8.8% and CRT-D implantations by 29.3%. Regional variations
Abbreviations: ALD, long-term illness scheme; ICD 10, International Classiﬁcation of Diseases, 10th revision; CRT, cardiac resynchro-
nization therapy; CRT-D, cardiac resynchronization therapy with triple-chamber cardioverter-deﬁbrillator; CRT-P, cardiac resynchronization
therapy with triple-chamber pacemaker; HAS, Haute Autorité de santé; NHI, National Health Insurance; pmi, per million inhabitants; PMSI,
Programme de médicalisation du systeme d’information.
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in implantation rates were observed regarding single-chamber pacemakers (15—33%) and CRT-D
among CRT (46.2—73.8%). Pacemaker implantations cost D 158.4 million overall, 4.5% of which
was for CRT-P; cardioverter-deﬁbrillator implantations cost D 96 million, 49% of which was for
CRT-D. For NHI beneﬁciaries, 11.9% of CRT-P patients and 6.5% of CRT-D patients already had a
device of the same type implanted in the 3 preceding years.
Conclusion.— The results conﬁrm the increase in cardioverter-deﬁbrillator implantations in
France. The implantation rate remains lower than that in the USA but falls within the European
average. Reasons behind signiﬁcant regional variations in implantation rates need further study.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Justiﬁcation.— L’implantation de dispositifs cardiaques est susceptible d’augmenter fortement
face au vieillissement de la population et à l’élargissement des indications.
Méthode.— Les malades ont été identiﬁés à l’aide du PMSI en 2008 et 2009 pour le calcul des
taux nationaux d’implantation, puis les bénéﬁciaires du régime général (76 % de la population)
ont été retenus pour l’étude des caractéristiques des patients implantés.
Résultats.— Parmi les 64 306 implantations de stimulateurs (1003,7 par million d’habitant
[pmh]) en 2009, 21,4 % concernaient des simple chambre (214,5 pmh), 75,4 % des double
(756,7 pmh) et 3,2 % des triple (CRT-P, 32,7 pmh). En 2009, 9028 déﬁbrillateurs ont été implantés
(140,8 pmh) dont 30,1 % en simple chambre (42,3 pmh), 27,5 % en double (38,6 pmh) et 42,5 %
en triple (CRT-D, 59,8 pmh). Ces derniers totalisaient 65 % des resynchronisateurs. Entre 2008 et
2009, la pose de CRT-P a augmenté de 8,8% et celle de CRT-D de 29,3%. Il existait des variations
régionales des taux d’implantation et de la proportion de simple chambre parmi les stimula-
teurs (15—33%), des triple chambre parmi les déﬁbrillateurs (14,9—59,2 %) et de ces derniers
parmi les resynchronisateur (46,2—73,8 %). Le coût global était de 158,4 millions d’euros pour
les stimulateurs, dont 4,5 % pour les CRT-P, et de 96 millions pour les déﬁbrillateurs, dont 49 %
pour les CRT-D. Pour les bénéﬁciaires du régime général, 58,6 % des déﬁbrillateurs ont été
implantés en prévention primaire; concernant les resynchronisateurs, 11,9 % des malades avec
CRT-P avaient eu une implantation d’un appareil du même type les trois années précédentes et
6,5 % pour les CRT-D.
Conclusion.— En France, l’augmentation de l’implantation de déﬁbrillateurs se conﬁrme. Le
taux reste inférieur à celui des États-Unis, mais dans la moyenne européenne. Les fortes dis-
parités régionales d’implantation restent à explorer, comme dans d’autres pays, ainsi que le
taux de réimplantation.
© 2011 Elsevier Masson SAS. Tous droits réservés.
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[Introduction
Implantable cardiac devices can be distinguished by two
main types: pacemakers for treatment of bradycardia and
cardioverter-deﬁbrillators for additional treatment of ven-
tricular arrhythmias. There are single- or dual-chamber
devices, according to the number of chambers stimulated
with pacing leads. Cardiac resynchronization therapy (CRT)
directly stimulates three of the heart chambers with either
a triple-chamber pacemaker (CRT-P) or a triple-chamber
cardioverter-deﬁbrillator (CRT-D). Excepting possible varia-
tions in the prevalence of cardiac diseases treated by these
devices, the ageing of the French population implies a regu-
lar increase in the number of target individuals. In addition,
recommended indications for CRT and deﬁbrillation have
been extended.
CRT with the addition of left ventricular pacing through
coronary sinus lead insertion was previously reserved for
patients with severe heart failure with left ventricular sys-
tolic dysfunction and electrical ventricular asynchronism
(wide QRS complex). It has now been sufﬁciently demon-
i
t
dtrated that implanting these patients in the earlier phases
f the disease signiﬁcantly limits its progression [1,2]. Sim-
larly, in the past 10 years, the systematic implantation of
ardioverter-deﬁbrillators has no longer been exclusively
imited to secondary prevention (i.e. cases of serious ven-
ricular tachycardia or cardiac arrest) but has evolved to
nclude primary prevention [3,4]. As heart failure is a major
ause of ventricular arrhythmias, the combination of deﬁb-
illator implantation with CRT is frequently debated [5,6].
owever, no randomized controlled clinical trials designed
o speciﬁcally compare implantations of multisite pacemak-
rs and multisite deﬁbrillators (CRT-P vs. CRT-D) have been
arried out among patients with heart failure [7]. Thus,
ecent national data concerning these devices exist in a con-
inuously evolving context; nevertheless, the data are sparse
8—13].
The aim of this study is to determine implantation rates
n patients between 2008 and 2009 in France and, using
he National Health Insurance (NHI) Information System
atabase, patient proﬁles and associated medications.
3M
D
T
a
e
p
p
p
d
b
(
[
t
c
I
s
I
P
T
t
i
t
c
7
i
d
d
w
A
(
t
t
6
p
a
V
T
s
d
p
c
c
u
(
d
t
a
a
p
e
I
c
g
d
a
b
I
s
a
c
v
c
w
a
s
a
t
o
i
ﬁ
(
c
c
e
i
a
c
s
a
n
d
i
t
a
i
t
a
d
s
y
d
a
a
w
m
o
w
S
I
r
t
f
R
r
f
c
d34
ethods
ata sources
he NHI Information System Database (SNIIRAM) contains
nonymous, exhaustive, personal data on all healthcare
xpenditure claims by beneﬁciaries for the past 2 years
lus the current year [14]. Other information, such as
atients’ area of residence or co-payment exonerations for
atients covered by the long-term illness scheme (affection
e longue durée [ALD]) are also available. These data can
e matched to French National Hospital Discharge database
Programme de médicalisation du système d’information
PMSI]) data through a unique anonymous number allocated
o each individual. Medical diagnoses and listed long-term
hronic diseases (ALD scheme) are coded according to the
nternational Classiﬁcation of Diseases (10th revision with
ome extensions introduced by the Technical Hospitalization
nformation Agency, www.atih.sante.fr; [ICD10]).
opulation
he PMSI database enabled the use of the whole popula-
ion as a sample base. It provided the annual number of
mplantations and the rate of implanted patients in France
ogether with regional variations. The study of patient
haracteristics concentrated on NHI beneﬁciaries, covering
6% of the French population in 2008 (around 48 million
nhabitants). In 2009, 74,482 pacemaker and cardioverter
eﬁbrillator implantations were identiﬁed through the PMSI
atabase for 73,826 valid hospital stays, excluding those
ith an invalid patient number or with distinct devices.
fter selecting the last admission with device implantation
the most recent stay if the patient was hospitalized several
imes), 73,334 hospitalizations or patients were included in
he study. In 2008, 70,409 implantations corresponding to
9,181 valid hospitalizations were identiﬁed and 68,756 hos-
italizations or patients were retained after the selected
dmission.
ariables analysed
he implantation of a cardiac device was identiﬁed through
peciﬁc billing data for public and private hospitals. Billing
ata permits the identiﬁcation of the speciﬁc types of
acemaker or deﬁbrillator implanted (single-chamber, dual-
hamber or triple-chamber, according to the number of
hambers stimulated, i.e. the number of pacing leads
sed) coded by means of the products and services list
LPP).
The existence of heart disease and the nature of this
isease were identiﬁed through the list of chronic long-
erm diseases eligible for coverage under the ALD scheme,
nd by means of medical diagnosis codes for the selected
dmission and all hospitalizations occurring in the 36 months
rior to implantation. The following disease groups were
stablished: valvular heart disease (ICD10 codes I05 to
08, I34 to I39), ischaemic cardiomyopathy (I20 to I25),
ardiomyopathy (I42 and I43) and heart failure (I50). Sub-
roups were speciﬁcally added for electrocardiographic
isorders, from the ICD10 codes: sinoatrial blocks (I495),
trioventricular blocks (I440 to I443, I458 and I459), bundle
p
a
i
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ranch blocks (I444 to I455), cardiac arrest (I460, I461 and
469), ventricular tachycardia (I470, I472, I490 and I493),
upraventricular tachycardia (I471, I479, I48, I491 and I492),
nd the category ‘other’, which included the remaining
odes (mostly non-disease-speciﬁed). Cardiac surgical inter-
entions other than device implantations (valvular surgery,
oronary artery bypass graft) and coronary angioplasties
ere searched for during the 36 months prior to the selected
dmission.
Prescription drugs administered for heart conditions were
earched for during the 6 months preceding the selected
dmission and during the 6 months after. For each of these
wo periods, the reimbursement claims for at least 3 months
f treatment were tested for each class of prescription drug
dentiﬁed by its Anatomical Therapeutic Chemical Classi-
cation code: beta-blockers; other antiarrhythmic agents
Vaughan-Williams classiﬁcation—class I: quinidine, lido-
aine, ﬂecainide, etc.; class III: amiodarone and sotalol;
lass IV: calcium channel blockers); angiotensin-converting
nzyme inhibitors or angiotensin-receptor blockers; diuret-
cs; cardiotonic digitalis; antiplatelet agents; and oral
nticoagulants.
Comorbidity was identiﬁed as follows: the presence of
ancer was identiﬁed through patients qualiﬁed for ALD
cheme coverage starting at last 2 years before the selected
dmission and/or hospitalized with a cancer principal diag-
osis code and/or radiotherapy or chemotherapy delivered
uring the course of the year. Alzheimer’s disease was
dentiﬁed through tracer drug prescriptions on at least
wo different dates and/or disease-speciﬁc ALD coverage
nd/or a speciﬁc hospitalization. Parkinson’s disease was
dentiﬁed through disease-speciﬁc ALD coverage and/or
racer drugs prescribed on three different dates. Asthma
nd chronic obstructive pulmonary disease, diabetes and
epression were identiﬁed through the delivery of disease-
peciﬁc drugs at least three times during the course of the
ear. End-stage renal disease was identiﬁed by means of
isease-speciﬁc ALD coverage, delivery of regular dialyses
nd reimbursement claims for immunosuppressors associ-
ted with a kidney transplant. Symptoms of inﬂammation
ere deﬁned by the existence of at least nine reimburse-
ent dates for anti-inﬂammatory drugs during the course
f the year. Chronic hepatic disease and psychotic disorder
ere identiﬁed through disease-speciﬁc ALD coverage.
tatistical analysis
mplantation rates were standardized by sex and age for
egional comparisons using the estimated French popula-
ion on 1 January 2008 supplied by the National Institute
or Statistics and Economic Research (http://www.insee.fr).
egional analyses were performed using the area of
esidence, not the place where the implantation was per-
ormed. Patient proﬁles and treatment characteristics were
ompared for the different types of implantable cardiac
evices using the Chi2 test and the Wilcoxon test. For com-
arisons between the periods before and after the selected
dmission, only patients still on record 6 months after the
mplantation date were included. Analyses were done using
AS software (version 9.1.3, SAS Inc., Cary, NC, USA).
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Table 1 Number and rates of patients with hospital admission for cardiac device implantation by device type in 2008
and 2009.
Implantable cardiac device 2008 2009 Evolution
N % Ratesa N % Rates* %
Pacemaker, single chamber 13,175 21.5 205.7 13,739 21.4 214.5 4.3
Pacemaker, dual chamber 46,161 75.4 720.2 48,484 75.4 756.7 5.0
CRT-P 1915 3.1 30.0 2083 3.2 32.7 8.8
Total pacemakers 61,251 100.0 955.7 64,306 100.0 1003.7 5.0
Cardioverter-deﬁbrillator, single chamber 2320 30.9 36.1 2714 30.1 42.3 17.0
Cardioverter-deﬁbrillator, dual chamber 2221 29.6 34.7 2481 27.5 38.6 11.7
CRT-D 2964 39.5 46.2 3825 42.5 59.8 29.3
Total cardioverter-deﬁbrillators 7505 100.0 116.9 9028 100.0 140.8 20.3
Cardiac resynchronization (CRT-P and CRT-D) 4879 76.1 5908 92.4 21.1
Total 68,756 1072.6 73,334 1144.5 6.7
CRT-D: cardiac resynchronization therapy with triple-chamber cardioverter-deﬁbrillator; CRT-P: cardiac resynchronization therapy with
triple-chamber pacemaker.
a per million inhabitants.
R
i
T
5
h
r
i
p
n
b
A
P
w
T
c
p
e
m
t
a
f
r
t
s
o
e
(
d
o
s
p
mResults
Types of device and implantation rates
The baseline characteristics and primary reason for hospital-
ization are shown in Table 1. In 2009, pacemakers accounted
for 88% of patients with a cardiac device implantation. The
national rate was 1003.7 per million inhabitants (pmi), of
which 21.4% were single chamber, 75.4% dual chamber and
3.2% CRT-P. Between 2008 and 2009, the number of patients
implanted with a pacemaker increased by 5.0% and, more
particularly, by 4.3% for single-chamber pacemakers and
8.8% for CRT-P.
In 2009, 9028 patients (140.8 pmi) were implanted
with cardioverter-deﬁbrillators, of which 30.1% were single
chamber, 27.5% dual chamber and 42.5% CRT-D. Between
2008 and 2009, there was a global increase of 20.3% in the
number of patients with a cardioverter-deﬁbrillator implan-
tation, and, in particular, an increase of 29.3% in CRT-D.
Concerning CRT, 5908 patients were implanted (92.4 pmi),
of whom 64.8% received CRT-D.
Regional variations in implantation rates for
each device type
In 2009, after standardization of age and sex, marked
regional disparities in patient implantation rates for each
of the three main types of device were found (Table 2).
For pacemaker implantations, regional rates were below
550 pmi outside metropolitan France and ranged between
764 pmi (Auvergne) and 1168 pmi (Lorraine) in metropolitan
France. After adjustment for age and sex, the percentage of
single-chamber pacemaker implantations varied from 15.4%
in Île-de-France to 33.4% in Champagne-Ardenne (Fig. 1).
The highest regional implantation rates for all types of pace-
maker were recorded in the west and south-west regions and
also in the north-east.
The implantation rate for cardioverter-deﬁbrillators was
less than 80 pmi in the French West-Indies. In contrast,
C
y
o
teunion Island had the highest cardioverter-deﬁbrillator
mplantation rate (207 pmi), ahead of Auvergne (194 pmi).
he proportion of CRT-D varied between 14.9% in Alsace and
9.2% in Aquitaine. Regional CRT-D implantation rates were
ighest in the central, south-east and south-west Atlantic
egions of metropolitan France, and low in the west. CRT
mplantation rates ranged between 29 pmi (Alsace) and 177
mi (Réunion Island). Regional rates were lowest in the
orthern half of France; the percentage of CRT-D varied
etween 46.2% in Pays de la Loire and 73.8% in Provence-
lpes-Côte d’Azur.
roﬁles of National Health Insurance patients
ith an implantable cardiac device
he patient characteristics and medical history by type of
ardiac device are given in Table 3. Fifty-six per cent of
atients implanted with single or dual-chamber pacemak-
rs and 66.5% of those who received CRT-P were men. The
ain indications were sinoatrial block and atrial ﬁbrilla-
ion (76.4% for single chamber, 45.3% for dual chamber)
nd paroxysmal or permanent atrioventricular block (36%
or single chamber, 50.8% for dual chamber). Patients who
eceived CRT-P were younger (mean age 75.5 years) than
hose with a dual-chamber pacemaker (77.0 years) or a
ingle-chamber pacemaker (80.2 years). With the exception
f CRT-P, women were older. Single-chamber pacemak-
rs were more frequently implanted in a public hospital
55.5%) than dual-chamber pacemakers (48.2%). A cardiac
evice implantation of the same type in the 3 previ-
us years was found for less than 2% of patients with a
ingle- or dual-chamber pacemaker but for 11.9% of CRT-P
atients.
Patients with a cardioverter-deﬁbrillator were mostly
en: 81.3% single-chamber, 84% dual-chamber and 79.9%
RT-D. CRT-D patients were on average older (66.0
ears) than patients with a dual-chamber (62.7 years)
r single-chamber (57.8 years) deﬁbrillator. For each of
he three types of cardioverter-deﬁbrillator device, 50%
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P.
Tuppin
et
al.
Table 2 Rates of cardiac device implantation per million inhabitants in 2009 in France, according to cardiac device type and region of residence.
Pacemakers Cardioverter-deﬁbrillators Cardiac resynchronization therapy
N Rates(pmi)a pb Single chamberc (%) pb N Rates(pmi)a pb CRT-Dc (%) pb N Rates(pmi)a pb CRT-Dc(%) pb
Réunion 187 526 - 20 109 207 + 55 * 75 177 + 70
Auvergne 1273 764 - 33 *** 298 194 + 44 176 118 + 68
Rhône-Alpes 5017 854 - 25 *** 1132 190 + 44 694 125 + 74 **
Languedoc-Roussillon 2836 923 - 21 522 183 + 37 281 100 68
Aquitaine 4252 1121 + 19 *** 642 182 + 59 *** 550 162 + 71
Provence Alpes Côte d’Azur 5538 970 17 *** 934 173 + 44 620 119 + 74 **
Nord Pas de Calais 3521 1039 + 23 602 167 + 30 *** 251 76 - 68
Centre 2697 926 - 22 435 159 + 44 315 119 + 62
Midi-Pyrénées 3365 994 22 416 136 38 277 92 57
Guyane 20 343 - 17 11 136 27 3 45 84
Champagne-Ardenne 1475 1091 + 33 *** 181 133 34 84 66 - 69
Bourgogne 1898 940 27 *** 244 132 42 166 92 65
Corse 319 887 18 47 129 50 38 111 62
Haute-Normandie 1561 911 - 24 * 226 128 41 114 69 - 72
Franche-Comté 943 796 - 26 ** 153 127 22 *** 57 50 - 60
Limousin 1233 1167 + 30 *** 106 118 45 75 84 63
Ile de France 9699 1096 + 15 *** 1145 118 - 53 *** 923 107 + 65
Lorraine 2641 1168 + 23 280 117 - 39 192 86 54 *
Pays de la Loire 3177 874 - 18 *** 415 117 - 40 379 112 + 46 ***
Poitou-Charentes 2504 1119 + 26 *** 226 115 - 40 148 75 - 59
Picardie 1576 922 - 23 207 113 - 36 97 58 - 66
Alsace 1689 1045 + 27 *** 190 105 - 15 *** 48 29 - 54
Bretagne 2806 812 - 29 *** 315 96 - 38 221 69 - 49 **
Basse-Normandie 1566 949 22 125 80 - 43 99 65 - 53
Martinique 182 546 - 18 29 78 - 24 14 44 - 52
Guadeloupe 141 445 - 33 ** 13 37 - 55 10 34 - 63
France 62,116 971 22 9003 141 42 5907 92 67
CRT-D: cardiac resynchronization therapy with triple-chamber cardioverter-deﬁbrillator; pmi: per million inhabitants.
p < 0.05; **p < 0.01; ***p < 0.001.
a Rates pmi are standardized by age and sex of French population.
b Rates signiﬁcantly higher (+) or lower (-) than the national rate.
c Rates standardized by age and sex of patients for the device type studied.
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Figure 1. Rates of cardiac device implantation per million inhabitants (pmi) in 2009 in France, according to cardiac device type and
French department of residence. Rates pmi are standardized by age and sex of French population. CRT-D: cardiac resynchronization therapy
with triple-chamber cardioverter-deﬁbrillator; CRT-P: cardiac resynchronization therapy with triple-chamber pacemaker.
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Table 3 Patient characteristics and medical history by type of cardiac device implanted in 2009 in France.
Pacemakers Cardioverter-deﬁbrillators
Single Ch. Dual Ch. CRT-P pa Single Ch. Dual Ch. CRT-D pa
N 8371 31,646 1356 1993 1779 2740
Men (%) 56.6 55.4 66.5 *** 81.3 84.0 79.9***
Mean age (years) 80.2 77.0 75.5 *** 57.8 62.7 66.0***
Standard error 11.2 10.9 10.6 14.3 13.2 10.5
Mean age, men (years) 79.1 75.8 75.5 *** 58.3 63.1 65.8***
Standard error 10.7 10.6 10.8 13.9 12.6 10.5
Mean age, women (years) 81.6 78.3 75.5 *** 55.4 60.4 66.8***
Standard error 11.5 11.0 10.1 15.8 15.8 10.2
Hospital type (%)
University hospital 17.9 15.7 35.0 *** 69.0 54.0 53.4***
Community hospital 37.6 32.5 24.0 14.9 21.1 16.4
Private clinic 44.5 51.8 41.1 16.2 24.9 30.3
Mean length of stay (days) 7.4 6.1 7.5 *** 6.7 7.2 6.9***
Standard error 9.6 7.2 8.2 8.4 8.7 7.7
Device implantation 36 months beforeb (%)
All types 1.7 1.3 12.5 *** 3.1 5.1 11.5***
Same type 1.7 1.3 11.9 *** 2.4 2.9 6.5***
Heart disease (%)
Valvular heart disease 21.1 15.6 33.6 *** 14.4 17.4 27.5***
Ischaemic cardiopathy 31.0 30.8 54.2 *** 65.6 72.2 64.1***
Cardiomyopathy 12.7 9.6 66.3 *** 41.1 42.3 71.4***
Heart failure 38.1 22.1 82.8 *** 54.4 53.3 87.0***
Electrocardiographic disorders 91.3 87.4 79.0 *** 68.8 78.9 79.1***
Sinoatrial blocks or supraventricular tachycardia 76.4 45.3 54.0 *** 29.6 38.2 44.1***
Atrioventricular blocks 36.0 50.8 29.1 *** 5.4 12.4 20.5***
Branch blocks 10.8 15.8 33.6 *** 9.2 10.5 35.9***
Cardiac arrest or ventricular tachycardia 5.3 4.7 9.4 *** 46.3 56.5 27.6***
Others 10.5 6.3 6.7 *** 11.1 12.9 8.8***
Cardiac surgery 36 months beforeb (%) 3.7 4.1 5.4 *** 5.8 6.7 5.5
Catheterization 36 months beforeb (%) 2.4 4.3 10.2 *** 20.2 20.0 13.5***
Comorbidity (%)
Neoplasia 6.3 6.1 4.9 3.4 3.3 3.7
Diabetes mellitus 20.1 20.5 25.1 *** 20.5 20.2 27.5***
End-stage renal disease 0.9 1.0 0.7 0.9 0.8 1.0
Chronic obstructive pulmonary disease 12.2 11.1 16.3 *** 11.8 12.3 16.6***
Alzheimer’s disease 7.6 4.8 2.4 *** 0.3 0.3 0.5
Parkinson’s disease 2.5 2.1 2.1 0.4 0.3 0.5
Depression 16.7 15.6 15.3 * 12.2 10.5 13.2 *
Anti-inﬂammatory use 2.1 2.8 3.0 *** 1.9 1.7 2.2
Chronic hepatic disease 0.7 0.5 0.7 0.6 0.8 0.5
Psychotic disorder 2.3 2.3 1.3 3.3 3.0 2.1 *
Ch.: chamber: CRT-D: cardiac resynchronization therapy with triple-chamber cardioverter-deﬁbrillator; CRT-P: cardiac resynchronization
therapy with triple-chamber pacemaker.
a *p < 0.05; **p < 0.01; ***p < 0.001.
b Before selected admission with device implantation.
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Cere implanted while the patient was in a university hos-
ital. In CRT-D patients, a prior implantation was more
requent (11.5%) than a prior deﬁbrillator implantation
6.5%). Considering ventricular tachycardia and cardiac
rrest as secondary prevention, the proportions of primary
revention implantations were 53.7% for single-chamber
evices, 43.7% for dual-chamber devices and 72.2% for
o
b
ariple-chamber devices (58.8% overall). The most frequent
eart conditions in patients with single-chamber implanta-
ions were heart failure (87%) and cardiomyopathy (71.4%).
RT-D patients were slightly younger than those with single-
r dual-chamber implants, and more frequently had dia-
etes (27.5%) or respiratory disease (16.6%). Between 2008
nd 2009, the percentage of CRT-D devices increased (38.1%
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Table 4 Patient treatment by type of cardiac device implanted in 2009 in Francea.
Pacemakers Cardioverter-deﬁbrillators
Single Ch. Dual Ch. CRT-P pc Single Ch. Dual Ch. CRT-D pc
N 7308 29,579 108 1882 1692 2536
Beta-blockersb (%)
Before implantation 31.6 32.0 63.1 *** 65.6 66.3 71.8 ***
After implantation 35.2 38.9 75.4 *** 81.1 87.2 85.8 ***
Other antiarrhythmic agents (%)
Before implantation 35.8 44.9 41.1 *** 22.3 34.9 33.3 ***
After implantation 31.9 50.1 37.7 *** 27.1 42.4 35.8 ***
Class I (%)
Before implantation 3.1 8.4 1.7 *** 1.7 3.2 0.8 ***
After implantation 1.3 7.9 0.4 *** 1.3 2.4 0.2 ***
Class III (%)
Before implantation 11.1 17.9 29.6 *** 12.6 23.6 25.2 ***
After implantation 9.1 24.4 30.3 *** 20.5 35.0 31.7 ***
Class IV (%)
Before implantation 27.6 29.1 15.8 *** 10.4 14.1 10.9 ***
After implantation 25.1 30.0 10.7 *** 7.5 10.0 6.2 ***
ACEI-ARB (%)
Before implantation 58.9 55.0 83.3 *** 66.5 70.1 85.4 ***
After implantation 58.1 56.5 83.9 *** 77.3 80.5 91.0 ***
Diuretics (%)
Before implantation 62.6 48.1 81.3 *** 51.1 50.5 81.8 ***
After implantation 64.8 49.1 84.8 *** 61.3 59.2 89.6 ***
Loop diuretics (%)
Before implantation 44.7 24.1 74.9 *** 42.7 40.2 76.3 ***
After implantation 50.9 28.8 79.1 *** 53.2 50.1 85.2 ***
Thiazide diuretics (%)
Before implantation 21.7 26.2 12.1 *** 7.6 9.0 9.9 *
After implantation 16.8 22.3 8.2 *** 5.3 6.0 6.0
Aldosterone receptor antagonist diuretics (%)
Before implantation 16.2 10.2 31.5 *** 24.3 23.1 40.9 ***
After implantation 16.0 9.6 31.5 *** 32.7 29.2 44.8 ***
Cardiotonic digitalis (%)
Before implantation 20.3 4.3 13.2 *** 5.0 2.4 9.9 ***
After implantation 15.8 3.8 10.8 *** 3.7 1.2 8.6 ***
Antiplatelet agents (%)
Before implantation 28.7 41.3 44.6 *** 50.9 57.0 51.0 ***
After implantation 29.3 44.5 44.5 *** 60.6 67.2 54.9 ***
Oral anticoagulants (%)
Before implantation 48.5 18.1 40.1 *** 24.4 22.4 38.1 ***
After implantation 54.0 24.6 43.9 *** 29.8 28.8 42.6
ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers; Ch.: chamber: CRT-D: cardiac resynchronization
therapy with triple-chamber cardioverter-deﬁbrillator; CRT-P: cardiac resynchronization therapy with triple-chamber pacemaker.
aExcluding patients lost to follow-up 6 months after the selected admission.
b Antiarrhythmic agents class II.
v
d
(
Mc *p < 0.05; **p < 0.01; ***p < 0.001
vs. 42.1%, p < 0.001), but not signiﬁcantly, and the percent-
age of secondary implantations decreased (45.6% vs. 41.2%,
p < 0.001).
A comparison between CRT-D and CRT-P patients allowed
us to observe for CRT-D patients: a younger mean age (66.0
vs. 75.5 years, p < 0.001), a higher percentage of men (79.9%
vs. 66.5%, p < 0.001), more frequent implantation in a uni-
versity hospital environment (53.4% vs. 35.0%, p < 0.001),
and a higher prevalence of ischaemic cardiomyopathy (64.1%
O
l
Ts. 54.2%, p < 0.001). The percentage of CRT-D among CRT
evices increased from 61.9% in 2008 to 66.9% in 2009
p < 0.001).
edications prescribedver 80% of patients with a cardioverter-deﬁbrillator — a
arge proportion of which had heart failure, as shown in
able 3— were prescribed a beta-blocker after implantation
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85.8% for CRT-D vs. 75.4% for CRT-P) (Table 4). They were
lso more frequently prescribed angiotensin-converting
nzyme inhibitors or angiotensin receptor blockers (91% for
RT-D vs. 83.9% for CRT-P). Patients with a CRT-D were
lso more frequently prescribed oral anticoagulants (42.6%
or CRT-D vs. 43.9% for CRT-P). After hospitalization, reim-
ursement claims for class I antiarrhythmic drugs were more
articularly found among patients with dual-chamber pace-
akers (7.9%) and claims for class IV drugs were more
articularly found among patients with a single-chamber
25.1%) or dual-chamber (30.0%) pacemaker.
ost
n 2009, the overall cost of implantable cardiac devices
hospitalization, device and leads) for NHI beneﬁciaries,
as estimated at D 254.8 million, with a 10.5% increase
etween 2008 and 2009 for an 8.7% increase in the num-
er of patients. More speciﬁcally, the average unit cost
or a single-chamber pacemaker was around D 3000 and
he total cost in 2009 was D 24.9 million (+6.8% between
008 and 2009). Respectively, dual- and triple-chamber
acemakers costs were D 4000/unit with a total cost of
126.4 million (+10.3%), and D 5300/unit with a total
ost of D 7.1 million (+6.3%); implantable cardioverter-
eﬁbrillator costs were D 12,000/unit with a total cost
f D 24.1 million (+6.9%) for single-chamber cardioverter-
eﬁbrillators, D 14,300/unit with a total cost of D 25.1
illion for dual-chamber cardioverter-deﬁbrillators (+3.1%)
nd D 17,300/unit with a total cost of D 47.2 million for CRT-
(+21,1%). It should be noted that the cost of an implantable
evice (device + pacing leads) represents approximately 55%
f overall hospitalization costs.
iscussion
his study conﬁrms the increase in the number of patients
mplanted between 2008 and 2009, with a marked increase
n cardioverter-deﬁbrillators, notably CRT-D. Regional vari-
tions are observed in implantation rates for the device
ubtypes, such as single-chamber pacemakers or CRT-D
mong CRT, and also in use for primary prevention. The total
nnual cost of implantable cardiac devices for NHI patients is
stimated at D 254.8 million with a 21.1% increase in CRT-D
mounting to D 47.2 million in 2009.
acemakers
he Haute Autorité de santé (HAS) estimated that the annual
umber of persons likely to beneﬁt from a single or dual-
hamber pacemaker implant in 2009 would be around 70,000
1100 pmi), with an annual growth rate of 2%, including
eplacements [10]. This study found fewer patients (62,223,
71 pmi). The average European sales rate for implantable
ardiac devices (947 pmi) was lower than the French rate
1037 pmi), which was, in turn, lower than the rates in Ger-
any (1234 pmi), Belgium and Luxembourg (1201 pmi) andtaly (1069 pmi). Between 2005 and 2009, the global annual
rowth rate in France for single- or dual-chamber pace-
aker sales was 2%— lower than the 4.9% found in this study
etween 2008 and 2009. These comparisons depend, among
s
7
pP. Tuppin et al.
ther things, on the demographic structure of the popula-
ion, the epidemiology of the heart diseases concerned, the
ssociated risk factors, practices and recommendations, the
ealth system and the social security system.
The HAS encourages practitioners to avoid the system-
tic use of dual-chamber pacemakers and encourages more
idespread use of single-chamber pacemakers in atrioven-
ricular blocks and sinoatrial blocks, while anticipating
ossible evolutions in the patient and the disease. Neverthe-
ess, this recommendation is still under debate in France.
he estimated implantation rate would thus be 25—30%
or single-chamber (236—297 pmi) and 70—75% for dual-
hamber pacemakers (700—800 pmi). Our study records
lower implantation rate for single-chamber pacemakers
22%) and only nine regions exceeded 25%. Spain recorded a
0% implantation rate in 2008 and Italy 32% in 2007 [15,16].
These same records registered the average age of
atients as 76.3 years in Spain and 77.6 years in Italy vs. 77.6
ears in France, with 56.9% being men in Spain and 57.1%
eing men in Italy, close to the 55.7% found in this study.
s expected, the most frequent conditions in patients who
eeded single- or dual-chamber pacemakers were sick sinus
yndrome and atrial ﬁbrillation (45.3% for dual-chamber)
s well as atrioventricular block (50.8% for dual-chamber).
panish records reported 54% atrioventricular block, 17%
trial ﬁbrillation and 20.9% sick sinus syndrome. Italian
ecords reported 46% atrioventricular block, 18.1% atrial
brillation and 26% sick sinus syndrome [15,16].
mplantable cardioverter-deﬁbrillators
he HAS estimated that the annual target population,
ncluding replacements, would be between 12,600 (200 pmi)
nd 18,900 patients (300 pmi), of whom 60% would have
single-chamber device, 15% dual-chamber and 25% CRT-D
7]. This study ﬁnds a considerably smaller effective tar-
et population of 9028 patients (140.8 pmi). The sales rate
or single- and dual-chamber deﬁbrillators (80.9 pmi) was
lso lower in France than the average European sales rate
eported by industry (149 pmi); it was inferior to those in
ermany (286 pmi), the Netherlands (208 pmi) and Italy (179
mi), but close to the sales rates in the United Kingdom (82
mi), and Spain and Portugal (73 pmi) [14]. Between 2005
nd 2009, the annual sales growth rate was 14% for single-
nd dual-chamber deﬁbrillators—lower than the European
rowth rate but close to the implantation rate between 2008
nd 2009 reported in this study.
Patient characteristics were similar to those reported
n existing registries [17,18]. Taking into account ﬁrst
mplantations and replacement implants, Spain recorded an
verage age of 61 years vs. 62.6 years in France. For sex,
taly and Spain respectively recorded 83% and 84% implan-
ations in men, slightly above the 81.4% ﬁndings in this study.
or patients with implantable cardioverter-deﬁbrillators,
eta-blockers represented the ﬁrst-line primary or sec-
ndary prevention antiarrhythmic treatment, especially in
he presence of associated left ventricular dysfunction,
hich explains the high prescription rates observed in this
tudy.
The HAS estimated primary prevention implantations at
0% for the implantable cardioverter-deﬁbrillator target
opulation [7]. In Italy, which has one of the high-
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hPacemaker and cardioverter-deﬁbrillator implantation in Fra
est implantation rates in Europe, 52% of implantable
cardioverter-deﬁbrillators were primary prevention implan-
tations compared with 79% in the USA [18,19]. Primary
prevention concerned 58.6% of patients in 2009 in our study.
This percentage varied from 26.3 to 81.7% between French
regions in 2009 and was highly signiﬁcantly (p = 0.003) cor-
related to regional variations in cardioverter-deﬁbrillator
implantation rates. In the case of CRT-D, the 42.5% found
here was higher than the percentage estimated by the HAS
(25%) and only ﬁve regions were below 30%. By comparison,
the CRT-D percentage was 39.8% in Italy and 29.3% in Spain
in 2007, and 38% in the USA in 2006 [17—19].
Cardiac resynchronization therapy
In 2009, the sales rate for CRT-P in France was higher than
the European average (36 pmi vs. 26 pmi) [7] but remained
stable between 2005 (34 pmi) and 2009 (36 pmi), as in most
other European countries. This study also found a low growth
rate for implantations (1.5%) between 2008 and 2009. On the
other hand, the French sales rate for CRT-D was below the
average European rate for 2009 (66 pmi vs. 85 pmi) and the
sales rates for Germany (127 pmi) and Italy (150 pmi), but
was higher than the sales rates for Spain (32 pmi) and the
United Kingdom (57 pmi). There is, nevertheless, a grow-
ing trend for CRT-D, as between 2005 and 2009, the annual
growth rate for sales in France reached 40%, higher than the
European growth rate (32%) and the 29% increase in implan-
tation rates between 2008 and 2009. It is thus probable that
in the long term, the percentage of CRT-D will continue to
increase together with overall costs, given that, compared
with a pacemaker, the additional cost for CRT-D is around
D 10,000. The choice of cardiac device is left to the clinician.
It should be noted that, in line with the CeRtITuDe study,
our ﬁndings show a preference for CRT-D implantations in
younger men with mild heart failure (New York Heart Associ-
ation classiﬁcation), commonly of ischaemic origin and with
less severe short-term prognosis and comorbidities [6]. The
10% prior implantation rate in the 3 previous years appears
relatively high for CRT-P and CRT-D. A possible explana-
tion could be a change in indications and, for example, an
upgrade from a traditional pacemaker to CRT and/or deﬁb-
rillator in the case of heart failure progression.
The deﬁnition of a target population for CRT is a subject
of debate [5,20—27]. National and international recom-
mendations have been developed and standardized since
2000 and, with the help of inclusion criteria established
during clinical trials, it is possible to estimate the theoret-
ical needs of the population. In the USA, after excluding
patients aged 80 years and over and comorbid patients,
the theoretical rate was estimated at 833 pmi [27], with
an annual rate of candidates for implantation estimated
at between 750 and 1000 pmi. With regard to France,
this represents an effective target population ranging from
45,000 to 63,000 patients; two to four times higher than
the estimated rate supplied by the HAS. In the absence of
major differences in cardiac mortality between the coun-
tries studied, several reasons are put forward to explain
variations in the implantation rate affecting the theoreti-
cal target population. These include geographical variations
in cardiac implantation equipment between countries (6.8
centres pmi in Germany vs. 1.4 pmi in France) or regions,
i
r
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elays in the communication and application of recommen-
ations, differences in health care ﬁnancing systems and the
ncreasing amount of health professionals’ time taken up
ith replacement implants. It has also been suggested that
atients likely to beneﬁt from a cardioverter deﬁbrillator
re not being referred to speciﬁc units. Numerous stud-
es have demonstrated the cost-effectiveness of CRT and
eﬁbrillators but further research is warranted to evaluate
he impact of indication extensions, particularly in patients
ith paucisymptomatic mild heart failure [23,26,27]. The
ntroduction of telecardiology in France should equally have
n impact on the cost-effectiveness of the management of
hese patients, and is currently under evaluation.
imitations
ompared with our results, sales ﬁgures provided by the
uropean Medical Technology Industry Association, Eucomed
6], report a higher number of devices sold in France in 2009:
037 pmi vs. 971.2 pmi for single- and dual-chamber pace-
akers, 36 pmi vs. 32.7 pmi for CRT-P, 88 pmi vs. 81 pmi
or single- and dual-chamber cardioverter-deﬁbrillators, and
6 pmi vs. 59.8 pmi for CRT-D, amounting to a total of
round 5000 additional devices. Our underestimation could
e explained by the fact that only one annual hospitaliza-
ion for implantation was taken into account in this study
nd some were excluded for having the wrong identiﬁca-
ion number. Even if we take into account the possibility
f a replacement implantation in the same year due to
evice-related problems or rapidly evolving clinical symp-
oms, the number of additional hospitalizations not included
n the study would not exceed 1200 devices, and given
he reimbursement system, it seems highly improbable that
% of implanted devices were not recorded in the PMSI
atabase. It could, however, be explained by stocking.
egarding the cardiac diseases affecting implanted patients,
t was decided to include those that qualiﬁed as a chronic
ong-term illness under the ALD scheme enriched with infor-
ation from diagnosis codes for prior hospitalizations over
3-year period prior to implantation. The speciﬁcity of
hese diagnoses, notably for cardiac arrhythmias, is natu-
ally subject to the quality and coding of the information
ollected. This study is unable to precisely identify primary
r secondary prevention implantations and primary preven-
ion implantations were obtained by eliminating the main
econdary prevention indications.
onclusions
he originality of this study lies in data matching several
edicoadministrative databases in order to enable exhaus-
ive monitoring of evolutions in cardiac device implantation
nd patient proﬁles, especially if the implanted devices
emain identiﬁable despite coding changes in the PMSI
atabase. The nature of the information collected does not,
owever, allow a detailed analysis, as a register would.In France, a high CRT-P implantation rate and an increase
n the CRT-D implantation rate were conﬁrmed. The CRT-D
ate remained within the European average but was lower
han that in the USA. Besides heterogeneity of implantation
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ate for primary prevention, reasons behind marked regional
isparities in implantation rates remain to be studied.
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